VEGF-A isoforms induce the expression of APLN in endothelial cells during human prenatal lung development.

Return to Grants

Publication Year:
2025
Authors:
PubMed ID:
41660010
Public Summary:
The lungs contain an extensive network of tiny blood vessels called capillaries that are essential for exchanging oxygen and carbon dioxide. Establishing this network during development is critical for preparing the lungs to function after birth. Recent research has identified two specialized types of capillary cells in the lung, but much remains unknown about how these cells develop in humans and what signals guide their formation. This study examined the role of vascular endothelial growth factor A (VEGF-A), a protein that helps regulate blood vessel development. VEGF-A exists in several different forms, called isoforms, which can have distinct biological functions. Studies in mice have suggested that individual VEGF-A isoforms help guide the development of specialized lung capillary cells. However, whether these findings also apply to the developing human lung has remained unclear. Using human prenatal lung tissues collected between 10 and 20 weeks of development, the study found that several VEGF-A isoforms increased at approximately the same time as molecular markers associated with specialized alveolar capillary cells, known as CAP2 cells. These changes were particularly evident around 18 to 20 weeks, an important developmental period when the lung begins establishing the thin barrier between air spaces and blood vessels that will eventually support gas exchange. To determine whether VEGF-A directly influences capillary development, human prenatal lung tissue was maintained in the laboratory and exposed to different VEGF-A isoforms. Several forms of VEGF-A increased the expression of APLN, a gene associated with specialized CAP2 cells and blood vessel formation. Importantly, imaging confirmed that this increase occurred specifically within cells lining the blood vessels. One isoform, VEGF-A121, produced a particularly strong increase in APLN, while VEGF-A189 showed evidence of reducing endothelial cell proliferation and altering cell characteristics. However, VEGF-A did not activate all of the molecular features associated with mature CAP2 cells. This suggests that the formation of these specialized capillaries is a complex process controlled by multiple signals rather than VEGF-A alone. The findings also reveal important differences between human and mouse lung development, demonstrating that VEGF-A isoforms do not always produce the same effects in the two species. Together, these findings provide new insight into how the human lung builds the blood vessel network necessary for breathing. Understanding the signals that guide normal lung vascular development may ultimately help identify why this process is disrupted in infants with developmental lung disorders and provide a foundation for future strategies aimed at promoting healthy lung growth and repair.
Scientific Abstract:
INTRODUCTION: Single-cell RNA-sequencing analyses have revealed the existence of two distinct capillary cell populations in the human lung: general capillary cells (CAP1) and alveolar capillary cells (CAP2). Studies in mouse have shown that the splicing of Vegf-a evolves during embryonic development, creating a temporal pattern of expression for different isoforms, which contributes to the formation of pulmonary capillaries. Moreover, it was demonstrated that murine Vegf-a188 isoform promotes the emergence of CAP2 in vitro. Human homologs of these VEGF-A isoforms exist; however, their role in this process remains elusive. This study investigates the role of VEGF-A and its isoforms in the differentiation of lung capillaries during human prenatal development. METHODS: A cohort of human prenatal tissues, aged from the late pseudoglandular to early canalicular stages of development (10-20 weeks of gestation), was used to study the emergence of CAP2 markers (TBX2, SOSTDC1, EDNRB, HPGD, APLN) in correlation with the expression of the different VEGF-A isoforms (VEGF-A121, VEGF-A145, VEGF-A165, VEGF-A189). RESULTS: RT-qPCR analyses revealed a simultaneous expression of certain VEGF-A isoforms with several CAP2 markers, which peaked at around 18-20 weeks of gestation. Human prenatal lung explants were then treated with recombinant proteins of the different VEGF-A isoforms to study their impact on EC proliferation, as well as on the expression of CAP2 markers. While most of the isoforms did not impact EC proliferation, except for VEGF-A189 which downregulated it, almost all of them upregulated the expression of APLN, a major CAP2 marker. By using fluorescence in situ hybridization, we showed that this increase of expression was specific to the ECs. However, most of the isoforms induced a downregulation of EDNRB and HPGD. They also did not impact the expression of SOSTDC1 and TBX2. DISCUSSION: Our study shows that the different VEGF-A isoforms do not have the same effect on human lung capillary differentiation as those observed with their homologs in mice, highlighting the importance of studying this process in the human model. Moreover, while it demonstrated that VEGF-A isoforms can induce APLN expression in ECs, it also revealed that CAP2 differentiation is most likely a multifactorial process, not only involving VEGF-A.